Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases
30 July, 2020
Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
29 July, 2020
44 shortlisted images from 13 countries; Categories are Social Perspectives, Hidden Worlds, Medicine in Focus, and two categories highlighting the 2020 theme of Mental Health;Winners to be announced digitally on 19 August
27 July, 2020
New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics
27 July, 2020
Molecular microbiologists at the University of Nottingham are working with biotech firm Cyanetics and Public Health England (PHE) to discover a novel antiviral medication to effectively treat Covid-19.
22 July, 2020
An international Covid-19 conference to consolidate key clinical learnings from across the globe will take place online on Monday 27 July from 16.00 hrs to 18.15 hrs (UK time). Hosted by the Royal Society of Medicine, the conference will draw together an international faculty of leading clinicians to distil the evidence and consider the lessons learned from the respiratory, cardiovascular and neurological responses to Covid-19.
21 July, 2020
Amsterdam, The Netherlands, 23 June 2020 - Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has been awarded a €3.1 million Innovation Credit from the Dutch Government. The funds will be used to advance the Company’s lead CD47/QPCTL immuno-oncology program through preclinical development towards human clinical studies.
15 July, 2020
Manchester’s world-class health innovation and precision medicine campus - a joint venture between Manchester University NHS Foundation Trust (MFT), the UK's largest NHS provider Trust, and Manchester Science Partnerships (MSP), took a step forward today as Citylabs 2.0 reached practical completion.
14 July, 2020
Optibrium’s StarDrop™ drug discovery software inspires the next generation of high-school students in their challenge to target COVID-19
13 July, 2020
Heart scans could improve care for patients and save lives. Half of Covid-19 patients who received a heart scan in hospital1 showed abnormalities in heart function, according to new research funded by the British Heart Foundation (BHF).
13 July, 2020
CPI today announced a partnership with Excivion Ltd, Cambridge, to optimise the manufacture of their novel Zika vaccine antigen candidate, Zika-HX, an integral component of any future vaccine formulation. Excivion’s technology could help to prevent future pandemics of deadly viruses by avoiding the adverse immune responses common in current vaccine candidates for Zika and related viruses.
13 July, 2020